Correlation of Platelet to Lymphocyte Ratio with Presence and Severity of Metabolic Syndrome

Yıl 2015, Cilt: 1 Sayı: 3, 18 - 24, 30.12.2015

Yasemin Kaya Osman Bektaş Ahmet Kaya Zeki Günaydın Adil Bayramoğlu Mustafa Çalgın

https://doi.org/10.19127/mbsjohs.32758

Cited By: 1

Öz

Objective: The aim of this study is to evaluate the relation between the components of Metabolic syndrome (MS) and the inflammation and the platelet-to-lymphocyte ratio (PLR) recognized as a novel marker of pro-thrombotic state.

Method: 70 patients with MS criteria were included in the study. 70 healthy people with matching age and gender characteristics were included in the study as the control group. The patients were divided into three groups with regard to the number of MS characteristics: Group 1 (the patients with three MS criteria), group 2 (the patients with four MS criteria), and group 3 (the patients with five MS criteria). PLR was calculated in regard to the complete blood count.

Results: The patients with MS had significantly higher PLR level compared to those without MS. However, PLR level were not associated with severity of MS. A moderate positive correlation was revealed between the severity of MS and PLR (r=0.419, p<0.001) and a strong positive correlation between the severity of MS and hs-CRP (r=0.562, p<0.001). Also, a positive correlation was detected between hs-CRP and PLR in our patient population (r=0.281, p=0.002). In order to specify the level of PLR to predict MS, ROC curve analysis was performed. The cut-off level for PLR with optimal sensitivity and specificity was calculated as 0,132 (Area under curve [AUC] =0.744 [0.655-0.833], p<0.001). For that level, the sensitivity was 73% and the specificity was 68, 4%.

Conclusion: This is the first study which determines the fact that there is a relation between MS criteria, the inflammation and PLR, which is a new marker of the pro-thrombotic state. There is also a positive correlation between PLR and hs-CRP in these patients. PLR may be beneficial in predicting the adverse cardiovascular cases in the patients with MS.

Anahtar Kelimeler

Metabolic Syndrome, Platelet/lymphocyte ratio, Inflammation

Kaynakça

• References:
• Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. Diabetes Care. 2003;26:1297-303.
• Hori Y, Nakatani K, Morioka K, et al. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med.2005;15:265-8.
• Calles-Escandon J, Mirza SA, Sobel BE, et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes.1998;47:290-3.
• Yudkin JS, Stehouwer CD, Emesis JJ, et al. C-reactive protein in healthy subjects; associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol.1999;19: 972-8.
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med.2005;352:1685-95.
• Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA199 levels and platelet-lymphocyte ratio. J Gastrointest Surg.2008;12:1422-8.
• Wang D, Yang JX, Cao DY, et al. Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther. 2013;6:211-6.
• Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34:326-34.
• Acar G, Kalkan ME, Avci A, et al. The Relation of Platelet-Lymphocyte Ratio and Coronary Collateral Circulation in Patients With Stable Angina Pectoris and Chronic Total Occlusion. Clin Appl Thromb Hemost. 2013;doi: 10.1177/1076029613508599
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Diagnosis, and Treatment of High Cholesterol in Adults: (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97.
• Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol.2004;44:2293-300.
• Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care. 2000; 23: 1835-9.
• Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation. 2003; 107: 391-7.
• Haffner SM. The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol.2006;97:3-11.
• Baker AR, Silva NF, Quinn DW, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006; 5:1-7.
• Mazurek T, Zhang L, Zalewski A, et al . Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460–2466.
• Fain JN, Sacks HS, Buehrer B, et al. Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes.2008; 32(5):810–815.
• Chan DC, Watts GF, Ng TW, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem.2005; 51:578-85.
• Desouza C, Pendergrass M, Fonseca V. The insulin resistance syndrome and its vascular complications. Am J Caridol.1999; 32:16-20.
• Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med.1999;340: 115-126.
• Vaughan DE. PAI-1 and cellular migration: dabbling in paradox. Arterioscler Thromb Vasc Biol. 2002; 22:1522-3.
• Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrin. 1996;7:157-61.
• Kishk YT, Trowbridge EA, Martin JF. Platelet volume subpopulations in acute myocardial infarction: an investigation of their homogeneity for smoking, infarct size and site. Clin Sci.1985;68:419-25.
• Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol.2005;46:284-90.
• Tsiara S, Elisaf M, Jagroop IA, et al. Platelets as predictor of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003; 9:17790.
• Acanfora D, Gheorghiade M, Trojano L, et al. Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. Am Heart J.2001;142:167-73.
• Ommen SR, Gibbons RJ, Hodge DO, et al. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am J Cardiol.1997; 79:812-4.